Lupin

Quick check

The five things to look at first. Open one for more.

• DebtLow debtIt owes ₹6,616 Cr against ₹22,448 Cr of shareholders' money (Mar 2026), 0.29 times.
• ResultsGrowingIn the Jun 2026 quarter, sales rose 32% and profit rose 16% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 47% of the company, about the same as in Jun 2025.
• ValuationCheap vs its pastThe share trades at 14.8 times its yearly earnings (P/E), cheaper than 100% of the time in the last 3 years. Its usual P/E is about 26.

Lupin against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)14.8 against a typical 34: cheaper than most peers (1st = cheapest).38th of 220
• Sales growth+32.1% against a typical +15.6% from a year earlier.53rd of 197
• Profit growth+16.1% against a typical +18.9% from a year earlier.88th of 160
• Share price, 3 months−19.4% against a typical −0.5%.179th of 200
• Size₹ 88,023.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).9th of 199

Exchange filings and their impact on the company.

• 24 Oct 2026General UpdatesLow impactNeutralPrice +1.6% on 26 Oct
  US FDA Goa inspection ends with just one observation, signalling no disruption.

  Lupin said the US FDA inspected its Goa manufacturing facility from October 19-23, 2026 and closed the inspection with one observation in Form 483. The company said it will respond within the stipulated timeframe and remains committed to CGMP compliance. With only one observation, the outcome points to normal operations continuing with no major regulatory overhang.

  Full analysisFiling
• 8 Oct 2026Press ReleaseLow impactPositivePrice +1% on 9 Oct
  Lupin won US FDA approval for a $52.3m injectable, adding small high-margin US sales.

  Lupin received US FDA approval for its generic Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL single-dose prefilled syringe for low blood clotting and vitamin K deficiency. The product was bioequivalent to the reference drug of International Medication Systems. The US market is about USD 52.3 million per IQVIA MAT August 2026, so the launch should add a small, likely high-margin contribution to US sales over the next year.

  Full analysisFiling
• 6 Oct 2026Press ReleaseLow impactPositivePrice +0.9% that day
  Lupin launched the world's first fixed-dose triple-combination COPD inhaler, strengthening its India respiratory franchise.

  Lupin launched Formoflo-G MDI, described as the world's first fixed-dose triple combination inhaler for COPD management. The press release dated October 6, 2026 did not disclose pricing or sales targets. The launch strengthens Lupin's core respiratory portfolio in India and should contribute incremental high-margin domestic sales over the next 12 months, though the scale is small relative to Lupin's ~Rs 30,000 crore revenue base.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Vinita D. Gupta

Chief Executive Officer, Executive Director

Ramesh Swaminathan

Executive Director, Global Chief Financial Officer, Chief Risk Officer and Head of API Plus SBU

Fabrice Egros

President - Corporate Development

Spiro Gavaris

President - US Generics

Claus Jepsen

President - Global Specialty

Cyrus Karkaria

President - Biotech Business

Yashwant Mahadik

President - Global Human Resources

Sofia Mumtaz

President - Legal and Compliance, Canada, ANZ and NEA Business